approved:A
sequence:S
immunogenicity:I


[A+ S+ I+] 5
1.trastuzumab
2.bevacizumab
3.canakinumab
4.ustekinumab
5.denosumab

[A- S+ I+] 1
cantuzumab


[A+ S+(in database) I-]  27
avelumab
sirukumab
dupilumab
romosozumab
bezlotoxumab
brodalumab
sarilumab
olaratumab
atezolizumab
ixekizumab

obiltoxaximab
daratumumab
necitumumab
idarucizumab
alirocumab
evolocumab
dinutuximab
secukinumab
nivolumab
blinatumomab

pembrolizumab
ramucirumab
vedolizumab
siltuximab
obinutuzumab
brentuximab vedotin
ipilimumab


[A+ S- I-] 14
reslizumab
mepolizumab
raxibacumab
pertuzumab
belimumab
tocilizumab
golimumab
catumaxomab
eculizumab
panitumumab
natalizumab
adalimumab
alemtuzumab
infliximab


